213 related articles for article (PubMed ID: 27485741)
1. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
Longoria TC; Tewari KS
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
[TBL] [Abstract][Full Text] [Related]
2. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041).
Yamazaki N; Takenouchi T; Fujimoto M; Ihn H; Uchi H; Inozume T; Kiyohara Y; Uhara H; Nakagawa K; Furukawa H; Wada H; Noguchi K; Shimamoto T; Yokota K
Cancer Chemother Pharmacol; 2017 Apr; 79(4):651-660. PubMed ID: 28283736
[TBL] [Abstract][Full Text] [Related]
3. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma.
Luke JJ; Ott PA
Oncotarget; 2015 Feb; 6(6):3479-92. PubMed ID: 25682878
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma.
Rutkowski P; Czarnecka AM
Expert Rev Anticancer Ther; 2023; 23(9):897-902. PubMed ID: 37573515
[TBL] [Abstract][Full Text] [Related]
5. Functional effects of immune complexes formed between pembrolizumab and patient-generated anti-drug antibodies.
Hock BD; McKenzie JL; Strother M; Goddard L; Butt L; Currie MJ
Cancer Immunol Immunother; 2020 Dec; 69(12):2453-2464. PubMed ID: 32556495
[TBL] [Abstract][Full Text] [Related]
6. KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma.
Long GV; Ferrucci PF; Khattak A; Meniawy TM; Ott PA; Chisamore M; Trolle T; Hyseni A; Heegaard E
Future Oncol; 2022 Oct; 18(31):3473-3480. PubMed ID: 36047545
[TBL] [Abstract][Full Text] [Related]
7. Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma.
Amber KT; Valdebran M; Lu Y; De Feraudy S; Linden KG
J Dtsch Dermatol Ges; 2018 Feb; 16(2):196-198. PubMed ID: 29389067
[No Abstract] [Full Text] [Related]
8. A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome.
Hansen E; Sahasrabudhe D; Sievert L
Cancer Immunol Immunother; 2016 Jun; 65(6):765-7. PubMed ID: 27067877
[No Abstract] [Full Text] [Related]
9. Pembrolizumab (Keytruda).
Kwok G; Yau TC; Chiu JW; Tse E; Kwong YL
Hum Vaccin Immunother; 2016 Nov; 12(11):2777-2789. PubMed ID: 27398650
[TBL] [Abstract][Full Text] [Related]
10. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report.
Martin-Liberal J; Furness AJ; Joshi K; Peggs KS; Quezada SA; Larkin J
Cancer Immunol Immunother; 2015 Jun; 64(6):765-7. PubMed ID: 25828465
[TBL] [Abstract][Full Text] [Related]
11. Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor-agnostic indication.
Hong YD; Enewold L; Halpern MT; Zeruto C; Mariotto AB
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5745. PubMed ID: 38156547
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy.
Patel K; Siraj S; Smith C; Nair M; Vishwanatha JK; Basha R
Crit Rev Oncog; 2019; 24(2):105-118. PubMed ID: 31679206
[TBL] [Abstract][Full Text] [Related]
13. Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone.
Rosner S; Sen F; Postow M
J Immunother Cancer; 2017; 5():34. PubMed ID: 28428883
[TBL] [Abstract][Full Text] [Related]
14. Complete response to immunotherapy in a nonagenarian patient with metastatic melanoma.
Foo T; Tapia Rico G; Brown MP
BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32699060
[TBL] [Abstract][Full Text] [Related]
15. Beneath the surface: a case report of metastatic iridociliary ring melanoma treated with pembrolizumab.
Parra-Bernal C; Aguilera-Partida JA; Dalvin LA; RodrÃguez-Reyes AA; Ancona-Lezama D
Arq Bras Oftalmol; 2024; 86(5):e20230046. PubMed ID: 35319657
[TBL] [Abstract][Full Text] [Related]
16. Immune interactions in pembrolizumab (PD-1 inhibitor) cancer therapy and cardiovascular complications.
Banerjee A; Narasimhulu CA; Singla DK
Am J Physiol Heart Circ Physiol; 2023 Oct; 325(4):H751-H767. PubMed ID: 37594487
[TBL] [Abstract][Full Text] [Related]
17. Challenging the standard of care in advanced melanoma: focus on pembrolizumab.
Abdul-Karim RM; Cowey CL
Cancer Manag Res; 2017; 9():433-442. PubMed ID: 29026335
[TBL] [Abstract][Full Text] [Related]
18. The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval.
Matias M; Pinho JO; Penetra MJ; Campos G; Reis CP; Gaspar MM
Cells; 2021 Nov; 10(11):. PubMed ID: 34831311
[TBL] [Abstract][Full Text] [Related]
19. This Month in JAAD International: July 2024: Immune checkpoint inhibitors.
Kantor J
J Am Acad Dermatol; 2024 May; ():. PubMed ID: 38763286
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
